Advertisement
News
Advertisement

Verisante Chosen as "Pick of the Street" in the Technology and Life Sciences Sector

Thu, 04/05/2012 - 6:45am
The Associated Press

(http://www.verisante.com/)

Verisante Technology, Inc.(http://www.verisante.com/) (TSX

VENTURE:VRS)(OTCQX:VRSEF)(PINKSHEETS:VRSEF)(FRANKFURT:V3T) (the

"Company" or "Verisante"), a leader in cancer detection technology,

announced today that the Company was named the "Pick of the Street" in

the Technology and Life Sciences Sector of the TSX Venture Exchange.

Following the official announcement of the 2012 TSX Venture 50 in

February, in which Verisante was named the top Technology and Life

Sciences Company, a selection of Canada's professional investment

community, including Fund managers, analysts, bankers, and retail

brokers were polled by Investor Relations firm, Equicom Group, to

select the "Pick of the Street" in each Venture 50 sector.

The "Pick of the Street" awards were announced at the TSX Venture 50

Spotlight event on April 3, 2012 in Toronto, where Verisante made a

presentation to an audience comprised of portfolio managers,

investment bankers, research analysts and investment advisors.

"We very much appreciate the recognition by the Canadian investment

community," said Thomas Braun, President and CEO. "With our Canadian

distributor in place and our Beta units currently in the process of

being tested and placed, Verisante continues to meet our key business

milestones as we work towards helping healthcare providers save lives

through the detection of some of the most common forms of cancer."

About Verisante Technology, Inc.

Verisante is a medical device company(http://www.verisante.com/about/)

committed to commercializing innovative systems for the early

detection of cancer(http://www.verisante.com/). The Verisante Aura

for skin cancer detection(http://www.verisante.com/products/aura/) and

the Verisante Core series for lung, colon and cervical cancer

detection(http://www.verisante.com/products/core/) utilize a

proprietary cancer detection platform while the operating software and

probe technology are unique to each device. The cancer detection

platform was developed by the BC Cancer Agency and tested and refined

at the Skin Care Centre at Vancouver General Hospital. This exclusive

platform technology allows Verisante to develop and offer a range of

compact, non-invasive cancer detection devices that offer physicians

immediate results(http://www.verisante.com/products/aura/) for many of

the most common cancers. The Aura has been approved for sale in

Canada, Europe and Australia. The Core has not yet been approved for

sale.

Verisante Aura was recently awarded Popular Science Magazine's "Best

of What's New

Award(http://www.popsci.com/bown/2011/product/verisante-aura)" for

2011, and Verisante Core was named one of the top 10 cancer

breakthroughs(http://verisante.com/news/72/canadian-cancer-society-names-verisante-core-a-top-10-cancer-breakthrough-of-2011-/)

of 2011 by the Canadian Cancer Society. In addition, the Company was

named a finalist for the 2011 Regional Awards for New

Technology(http://cme-mec.ca/?actionshow&lidJCKNC-E742G-1W6JA&cid39A7P-BQXJT-NYWII&comactionshow)

by the Canadian Manufacturers & Exporters and the National Research

Council of Canada and named as the year's top ranking Technology and

Life Sciences Company on the TSX Venture

50(http://www.tmx.com/en/news_events/news/news_releases/2012/2-15-2012_TMXGroup-2012Venture50.html).

Forward-Looking Statements

This release contains forward-looking statements, including, but not

limited to, statements regarding the future commercialization of

medical devices, the market demand for these products and the

proprietary protections the Company will obtain with regard to the

technology, all of which statements are subject to market risks, and

the possibility that the Company will not be able to obtain patent

protection or obtain sufficient customer demand. These statements are

made based upon current expectations and actual results may differ

from those projected due to a number of risks and uncertainties.

Advertisement

Share this Story

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading